BIOXYTRAN, INC.
Income Statement
| Line Item | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $191.1K | $246.5K | $255.8K | $275.6K | $417.3K | $312.9K | $76.3K | $16.1K |
| Cost of Revenue | $104.0K | $96.3K | $135.7K | $166.0K | $197.4K | $121.9K | $19.1K | $4.0K |
| Gross Profit | $87.1K | $150.2K | $120.1K | $109.6K | $219.9K | $191.0K | $57.2K | $12.1K |
| Gross Margin | 45.6% | 60.9% | 47.0% | 39.8% | 52.7% | 61.0% | 75.0% | 75.0% |
| Operating Expenses | ||||||||
| Research & Development | — | — | — | — | — | — | — | — |
| SG&A Expense | $397.7K | $821.5K | $2.2M | $1.4M | $2.2M | $2.5M | $4.5M | $341.1K |
| Operating Income | $-310.6K | $-671.3K | $-2.1M | $-1.3M | $-2.0M | $-2.3M | $-4.4M | $-329.0K |
| Operating Margin | -162.5% | -272.3% | -817.9% | -464.7% | -472.6% | -731.8% | -5,803.6% | -2,039.6% |
| Interest Expense | $7.8K | $7.8K | $7.8K | $7.8K | $12.7K | $3.5K | $6.4K | $8.4K |
| Pretax Income | — | $-696.8K | $-2.1M | $-1.3M | $-1.8M | — | — | — |
| Income Tax Expense | — | — | — | — | — | — | — | — |
| Net Income | $-318.4K | $-696.8K | $-2.1M | $-1.3M | $-1.8M | $-2.3M | $-4.4M | $-336.5K |
| Net Margin | -166.6% | -282.7% | -820.9% | -488.7% | -426.2% | -732.9% | -5,809.3% | -2,085.7% |
| EPS (Basic) | $-0.01 | $-0.03 | $-0.21 | $-0.30 | $-0.47 | $-0.02 | $-0.06 | $-0.01 |
| EPS (Diluted) | $-0.01 | $-0.03 | $-0.21 | $-0.30 | $-0.47 | $-0.02 | $-0.06 | $-0.01 |
| Shares Outstanding (Basic) | 85.1M | 28.2M | 12.3M | 5.8M | 3.9M | 161.3M | 113.9M | 34.4M |
| Shares Outstanding (Diluted) | 85.1M | 28.2M | 12.3M | 5.8M | 3.9M | 161.3M | 113.9M | 34.4M |
| Dividends Per Share | — | — | — | — | — | — | — | — |